In vitro: absence of AMF (309 kHz, 40 kA/m): 90% viability, under AMF action: 60% viability. Analysis performed based on the CCK-8 assayIn vivo: the inhibitory effect of the MG was analyzed on distant tumors and pulmonary metastases. A negative Ki-67 staining was achieved under AMF application, which proved the treatment efficiency obtained through the synergistic effect of pyrolysis and immunotherapy compared to the mice group that was treated only with MG, or MG loaded with PD-1 in the absence of AMF. The gene discussed is MKI67; the disease is myasthenia gravis.